Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

B. Ball · SciRah

Researcher profile · Semantic Scholar

B. Ball

Share profile

B. Ball — researcher profile on SciRah

h-index: 14
Works: 42
Citations: 694

Most-cited papers

Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
A. Burd, R. Levine, A. Ruppert, Alice S. Mims +36 more
2020Nature Medicine164 citations Open access
Semantic Scholar
Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure.
B. Ball, C. Famulare, E. Stein, M. Tallman +13 more
2020Blood Advances102 citations Open access
Semantic Scholar
Hypomethylating agent combination strategies in myelodysplastic syndromes: Hopes and shortcomings
B. Ball, A. Zeidan, S. Gore, T. Prebet
2016Leukemia and Lymphoma87 citations Open access
Semantic Scholar
Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia
I. Aldoss, Salman Otoukesh, Jian-Ying Zhang, S. Mokhtari +18 more
2021Cancer59 citations Open access
Semantic Scholar
Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax.
J. Bewersdorf, R. Shallis, A. Derkach, A. Goldberg +10 more
2022Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis28 citations Open access
Semantic Scholar
Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia.
B. Ball, R. Komrokji, L. Adès, M. Sekeres +10 more
2018Blood Advances28 citations Open access
Semantic Scholar
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates
Antoine N. Saliba, S. Kaufmann, E. Stein, Prapti A. Patel +36 more
2022Blood Advances20 citations Open access
Semantic Scholar
Which are the most promising targets for minimal residual disease-directed therapy in acute myeloid leukemia prior to allogeneic stem cell transplant?
B. Ball, E. Stein
2019Haematologica20 citations Open access
Semantic Scholar
Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia
J. McCarter, D. Nemirovsky, C. Famulare, N. Farnoud +23 more
2023Blood Advances19 citations Open access
Semantic Scholar
The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapy
B. Ball, M. Hsu, S. Devlin, M. Arcila +18 more
2021American journal of hematology/oncology19 citations Open access
Semantic Scholar
RAS Mutations Are Independently Associated with Decreased Overall Survival and Event-Free Survival in Patients with AML Receiving Induction Chemotherapy.
B. Ball, M. Hsu, S. Devlin, C. Famulare +10 more
2019Blood17 citations Open access
Semantic Scholar
Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML
J. Bewersdorf, S. Shimony, R. Shallis, Yi-Wen Liu +19 more
2024Blood Advances16 citations Open access
Semantic Scholar
Comparing Outcomes between Liposomal Daunorubicin/Cytarabine (CPX-351) and HMA+Venetoclax As Frontline Therapy in Acute Myeloid Leukemia
J. Grenet, A. Jain, M. Burkart, Julian A. Waksal +16 more
2021Blood16 citations Open access
Semantic Scholar
Venetoclax-based Salvage Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia Previously Treated with FLT3 or IDH1/2 Inhibitors
J. Bewersdorf, R. Shallis, A. Derkach, A. Goldberg +10 more
2022Leukemia and Lymphoma15 citations
Semantic Scholar
Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML)
B. Ball, Shukaib Arslan, Paul B. Koller, Dat Ngo +17 more
2022Leukemia and Lymphoma13 citations
Semantic Scholar
Precision Medicine Treatment in Older AML: Results of Beat AML Master Trial
A. Burd, R. Levine, A. Ruppert, Alice S. Mims +31 more
2019Blood11 citations
Semantic Scholar
Activating p53 and Inhibiting Superenhancers to Cure Leukemia
B. Ball, O. Abdel-Wahab
2018TIPS - Trends in Pharmacological Sciences10 citations Open access
Semantic Scholar
FLT3 Inhibitors as Maintenance Therapy after Allogeneic Stem-Cell Transplantation
A. Blackmon, I. Aldoss, B. Ball
2022Blood and Lymphatic Cancer : Targets and Therapy9 citations Open access
Semantic Scholar
Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia
A. Salhotra, N. Tsai, Jian-Ying Zhang, Dat Ngo +13 more
2021British Journal of Haematology8 citations Open access
Semantic Scholar
Trial in Progress: A Phase I Trial of BTX-A51 in Patients with Relapsed or Refractory AML or High-Risk MDS
B. Ball, A. Stein, G. Borthakur, C. Murray +3 more
2020Blood7 citations Open access
Semantic Scholar
Safety and Efficacy of CPX-351 in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia: An Updated Analysis
Amanda C. Przespolewski, A. Goldberg, Chetasi Talati, Salman Fazal +13 more
2021Blood5 citations
Semantic Scholar
Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing HMA
B. Ball, C. Famulare, E. Stein, M. Tallman +10 more
2019Blood5 citations
Semantic Scholar
Phase 1/2 Study Investigating CC-90011, a Potent, Selective, and Reversible Oral Inhibitor of Lysine-Specific Demethylase 1 (LSD1), Plus Concurrent Venetoclax (VEN) and Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML)
C. Dinardo, G. Borthakur, B. Ball, H. Erba +10 more
2021Blood4 citations Open access
Semantic Scholar
Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis
R. Komrokji, M. Melody, N. Al Ali, O. Chan +14 more
2021Leukemia and Lymphoma4 citations
Semantic Scholar
Initial Results from SELECT-AML-1, a Phase 2 Study of Tamibarotene in Combination with Venetoclax and Azacitidine in RARA-Positive Newly Diagnosed AML Patients Ineligible for Standard Induction Chemotherapy
S. Kambhampati, C. McMahon, A. Eghtedar, D. Pollyea +15 more
2022Blood2 citations Open access
Semantic Scholar
Outcomes of Venetoclax and Hypomethylating Agents (HMA) in Adult Patients with KMT2A-Rearranged Leukemias
B. Ball, Shukaib Arslan, Paul B. Koller, J. Murata-Collins +15 more
2021Blood2 citations Open access
Semantic Scholar
What Is the Optimal Treatment Modality in Molecularly Defined Secondary AML? a Multicenter Cohort Study
S. Shimony, J. Bewersdorf, R. Shallis, Yi-Wen Liu +14 more
2023Blood1 citations Open access
Semantic Scholar
Outcome of Patients Undergoing Hematopoietic Cell Transplantation for TP53-Mutated Acute Leukemias and MDS: Effect of Conditioning and GvHD Prophylaxis Regimens Intensity
Amrita J. Desai, Karamjeet S. Sandhu, Paul B. Koller, Dong-Yun Yang +17 more
2022Blood1 citations Open access
Semantic Scholar
Sinusoidal Obstruction Syndrome in Adult Patients with B-Cell Acute Lymphoblastic Leukemia Treated with Inotuzumab Prior to Hematopoietic Stem Cell Transplantation
V. Agrawal, H. Pourhassan, N. Tsai, Dat Ngo +20 more
2022Blood1 citations Open access
Semantic Scholar
Safety and efficacy of CPX-351 in younger patients (< 60 years) with secondary acute myeloid leukemia.
Amanda C. Przespolewski, A. Goldberg, Chetasi Talati, Salman Fazal +12 more
2022Blood1 citations Open access
Semantic Scholar
Current and Emerging Therapies for Acute Myeloid Leukemia.
B. Ball, M. Mei, Salman Otoukesh, A. Stein
2021Cancer treatment and research1 citations
Semantic Scholar
Evaluation of Salvage Induction Chemotherapy Regimens in Higher Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia after Hypomethylating Agent Treatment Failure
B. Ball, R. Komrokji, L. Adès, M. Sekeres +10 more
20161 citations
Semantic Scholar
Tamibarotene with venetoclax and azacitidine in RARA+ acute myeloid leukemia: results from the SY-1425-202 study
T. Cluzeau, U. Borate, Christine M. McMahon, P. Fenaux +20 more
2026Blood neoplasia0 citations Open access
Semantic Scholar
AML-055 Outcomes Based on Sequential Use of Venetoclax Based Therapy and Targeted Therapy in Acute Myeloid Leukemia (AML).
M. Stahl, R. Shallis, A. Derkach, A. Goldberg +10 more
2022Clinical Lymphoma, Myeloma & Leukemia0 citations
Semantic Scholar
Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia: an appraisal of the new WHO and IC classifications and ELN risk stratification
J. McCarter, D. Nemirovsky, C. Famulare, N. Farnoud +23 more
2022medRxiv0 citations Open access
Semantic Scholar
P492: TAMIBAROTENE IN COMBINATION WITH VENETOCLAX AND AZACITIDINE IN PREVIOUSLY UNTREATED ADULT PATIENTS SELECTED FOR RARA-POSITIVE AML WHO ARE INELIGIBLE FOR STANDARD INDUCTION THERAPY (SELECT AML-1)
E. Stein, S. de Botton, A. Pigneux, C. McMahon +16 more
2022HemaSphere0 citations Open access
Semantic Scholar
A Phase 1b Study of IDH Inhibition with Enasidenib and MEK Inhibition with Cobimetinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia Who Have Co-Occurring IDH2 and RAS Signaling Gene Mutations
B. Ball, E. Stein, Marjorie Robbins, Jian-Ying Zhang +6 more
2022Blood0 citations Open access
Semantic Scholar
Long Term Outcomes of Patients with Chronic Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation in the Era of Oral Tyrosine Kinase Inhibitors
Paul B. Koller, Haoyue Shan, Joycelynne Palmer, P. Curtin +23 more
2022Blood0 citations Open access
Semantic Scholar
Adverse Impact of Renal Impairment on Outcome of Patients Undergoing Melphalan-Based Reduced Intensity Allogeneic Hematopoietic Cell Transplantation
Tanya Markary, Tina Nguyen, N. Tsai, Shukaib Arslan +18 more
2022Transplantation and Cellular Therapy0 citations Open access
Semantic Scholar
AML-108 SELECT-AML-1 Trial in Progress: A Phase 2 Study of Tamibarotene in Combination With Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-Positive AML who are Ineligible for Standard Induction Therapy.
S. Kambhampati, Alireza Eghtedar, C. McMahon, S. de Botton +12 more
2022Clinical Lymphoma, Myeloma & Leukemia0 citations
Semantic Scholar
PHF6 Mutations Are Mutually Exclusive to TP53 Mutations, and Define a Distinct Subgroup of Secondary Acute Myeloid Leukemia Associated with a Primitive Stem/Progenitor Immunophenotype, Absent Complex Karyotype and Relatively Better Outcomes
W. Xiao, A. Goldberg, B. Ball, C. Famulare +7 more
2018Blood0 citations Open access
Semantic Scholar
Evaluation of Salvage Induction Chemotherapy Regimens in Myelodysplastic Syndrome and Acute Myeloid Leukemia after Hypomethylating Agent Treatment Failure
B. Ball, R. Komrokji, L. Adès, M. Sekeres +10 more
20170 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

E. Stein×20
Invite
E. Stein — researcher profile on SciRah
A. Goldberg×15
Invite
A. Goldberg — researcher profile on SciRah
I. Aldoss×13
Invite
I. Aldoss — researcher profile on SciRah
G. Marcucci×12
Invite
G. Marcucci — researcher profile on SciRah

×10

Invite

C. Famulare — researcher profile on SciRah

Invite

A. Stein — researcher profile on SciRah

Salman Otoukesh×8

Invite

Salman Otoukesh — researcher profile on SciRah

Invite

A. Salhotra — researcher profile on SciRah

Invite

H. Ali — researcher profile on SciRah

Paul B. Koller×8

Invite

Paul B. Koller — researcher profile on SciRah

Invite

R. Nakamura — researcher profile on SciRah

V. Pullarkat×8

Invite

V. Pullarkat — researcher profile on SciRah